Anti-Human CD49D (Integrin alpha 4) (Natalizumab) – APC
Anti-Human CD49D (Integrin alpha 4) (Natalizumab) – APC
Product No.: LT1103
- -
- -
Product No.LT1103 Clone Hu114 Target CD49D Product Type Biosimilar Recombinant Human Monoclonal Antibody Alternate Names CD49D; alpha 4 subunit of VLA-4 receptor; ITGA4; Integrin alpha-IV Isotype Human IgG4κ Applications FC |
- -
- -
Antibody DetailsProduct DetailsReactive Species Human Host Species Human Expression Host HEK-293 Cells FC Effector Activity Active Immunogen RAMOS cell line injected into mice. Product Concentration 0.2 mg/ml Formulation This Allophycocyanin (APC) conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative. Storage and Handling This Allophycocyanin (APC) conjugate is stable when stored at 2-8°C. Do not freeze. Regulatory Status Research Use Only (RUO). Non-Therapeutic. Country of Origin USA Shipping Next Day 2-8°C Excitation Laser Red Laser (650 nm) RRIDAB_2893888 Applications and Recommended Usage? Quality Tested by Leinco FC The suggested concentration for Natalizumab biosimilar antibody for staining cells in flow cytometry is ≤ 1.0 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application. Additional Reported Applications For Relevant Conjugates ? B Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Natalizumab. Natalizumab binds to the alpha 4 subunit of α4β1 and α4β7 integrins. This product is for research use only. Background Natalizumab is characterized as a disease-modifying therapy for multiple sclerosis (a disease of the central nervous system (CNS)), and inflammatory bowel disease. It works by inhibiting the migration of leukocytes to inflammation sites. The VCAM-1 and α4β1-integrin interaction is necessary for leukocyte adhesion, firm attachment, and transmigration across the blood-brain barrier into the CNS. Natalizumab, a recombinant, humanized antibody, binds to α4β1 -integrin and blocks its interaction with VCAM-1. Hence, leukocyte migration into brain tissue is inhibited, thereby reducing inflammation and preventing the formation of multiple sclerosis lesions.1 Inflammation in the gut pertaining to inflammatory bowel disease can be controlled in a similar fashion. Blocking α4β7-integrin with a humanized, monoclonal antibody, specific to the α4β7 heterodimer inhibits the migration of leukocytes into the inflamed intestinal tissue, thus, reducing inflammation in the gut.2 This cost-effective, research-grade Anti-Human CD49D (Natalizumab) utilizes the same variable regions from the therapeutic antibody Natalizumab making it ideal for research projects. Antigen Distribution CD49D is a subunit of the integrin VLA-4, which is expressed on the cell surfaces of stem cells, progenitor cells, T and B cells, monocytes, natural killer cells, eosinophils, and neutrophils. PubMed NCBI Gene Bank ID UniProt.org Research Area Biosimilars . Cell Adhesion . Cell Biology . Immunology . Innate Immunity References & Citations1. Hutchinson, M. (2007) Ther Clin Risk Manag. 3(2):259-68. 2. Vandervoort, M. et al. (2005) N Engl J Med 352:2499-507. Technical Protocols Certificate of Analysis |
Formats Available
- -
- -
Prod No. | Description |
|---|---|
LT1100 | |
LT1103 | |
LT1104 | |
LT1111 | |
LT1105 |
Products are for research use only. Not for use in diagnostic or therapeutic procedures.
